MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical EvidenceMCID

    Minimal Clinically Important Difference

    Smallest change in a measurement that patients perceive as clinically meaningful.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    MCID anchors interpretation of patient-reported outcomes and many functional endpoints. Pre-specifying MCID is increasingly expected by FDA and HTAs to interpret trial significance.
    What the regulation says
    Regulators like the FDA increasingly expect trial sponsors to pre-specify the Minimal Clinically Important Difference (MCID) in clinical trial protocols. This helps in interpreting the clinical significance of patient-reported outcomes (PROs) and other functional endpoints, moving beyond mere statistical significance. The EU Medical Device Regulation (MDR) also emphasizes the need for clinical benefit, which often involves considering MCID in assessing device effectiveness.

    What this means in practice

    Especially relevant for orthopedic, neuromodulation, and digital therapeutic trials with PRO-based endpoints.

    Examples

    • A manufacturer of a new orthopedic implant specifies an MCID of 10 points change on the Oxford Knee Score in their clinical trial protocol to demonstrate meaningful improvement in patient function. This pre-specified value guides the interpretation of the trial results regarding the implant's clinical benefit.
    • For a digital therapeutic aiming to reduce chronic pain, the sponsor defines an MCID as a 30% reduction in pain intensity on a Visual Analog Scale (VAS) to be considered clinically meaningful for patients.
    • An innovator developing a neuromodulation device for tremor identifies an MCID of 2-point improvement on a specific motor function scale, ensuring that the observed effect is perceptible and beneficial to the patient's daily life.
    Common pitfalls
    • •Confusing statistical significance with clinical significance, failing to recognize that a statistically significant difference may not be clinically meaningful.
    • •Not pre-specifying the MCID in the study protocol, leading to post-hoc, less robust interpretations of trial results.
    • •Using an MCID derived from a different patient population or intervention, which may not be appropriate for the current study.
    • •Failing to justify the chosen MCID value based on established methodologies or relevant clinical literature.
    • •Over-relying on a single MCID value without considering the broader context of patient experience and diverse outcome metrics.

    Frequently asked questions

    MCID helps determine if the observed effect of a MedTech product is not just statistically significant, but also meaningful and beneficial to the patient in a real-world clinical setting. This is crucial for demonstrating clinical utility and patient impact.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·1ICH·1ISO·1
    1. 1
      FDA PRO Guidance
      Verified
      FDAfda.gov
    2. 2
      ICH Guidelines
      Verified
      ICHich.org
    3. 3
      ISO 14155 Standard Page
      Verified
      ISOiso.org

    Inline markers like [1] jump to the matching reference above.